Arrowhead Adds Alpha-1 Antitrypsin Deficiency-associated Liver Disease to Pipeline | GenomeWeb

NEW YORK (GenomeWeb) – Arrowhead Research this week unveiled its newest pipeline program, a treatment for alpha-1 antitrypsin (AAT) deficiency-associated liver disease that will be developed with the support of a group called the Alpha-1 Project (TAP), which focuses on improving research into the condition.

Notably, Alnylam Pharmaceuticals, which is developing its own RNAi-based AAT therapeutic called ALN-AAT, this week announced its own partnership with TAP.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.